全文获取类型
收费全文 | 1024篇 |
免费 | 60篇 |
国内免费 | 35篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 70篇 |
妇产科学 | 3篇 |
基础医学 | 127篇 |
口腔科学 | 30篇 |
临床医学 | 140篇 |
内科学 | 164篇 |
皮肤病学 | 24篇 |
神经病学 | 35篇 |
特种医学 | 186篇 |
外科学 | 63篇 |
综合类 | 28篇 |
预防医学 | 55篇 |
眼科学 | 16篇 |
药学 | 47篇 |
中国医学 | 1篇 |
肿瘤学 | 123篇 |
出版年
2023年 | 3篇 |
2022年 | 8篇 |
2021年 | 16篇 |
2020年 | 8篇 |
2019年 | 11篇 |
2018年 | 22篇 |
2017年 | 17篇 |
2016年 | 15篇 |
2015年 | 23篇 |
2014年 | 18篇 |
2013年 | 36篇 |
2012年 | 25篇 |
2011年 | 23篇 |
2010年 | 51篇 |
2009年 | 42篇 |
2008年 | 29篇 |
2007年 | 42篇 |
2006年 | 35篇 |
2005年 | 54篇 |
2004年 | 28篇 |
2003年 | 15篇 |
2002年 | 19篇 |
2001年 | 25篇 |
2000年 | 13篇 |
1999年 | 21篇 |
1998年 | 48篇 |
1997年 | 48篇 |
1996年 | 49篇 |
1995年 | 34篇 |
1994年 | 41篇 |
1993年 | 36篇 |
1992年 | 13篇 |
1991年 | 15篇 |
1990年 | 10篇 |
1989年 | 24篇 |
1988年 | 45篇 |
1987年 | 20篇 |
1986年 | 15篇 |
1985年 | 28篇 |
1984年 | 6篇 |
1983年 | 5篇 |
1982年 | 10篇 |
1981年 | 10篇 |
1980年 | 12篇 |
1979年 | 10篇 |
1978年 | 8篇 |
1977年 | 10篇 |
1976年 | 14篇 |
1975年 | 4篇 |
1973年 | 2篇 |
排序方式: 共有1119条查询结果,搜索用时 187 毫秒
51.
52.
Kim D Harrison Beverly D Hiebert Arash Panahifar Janna M Andronowski Amir M Ashique Gavin A King Terra Arnason Kurtis J Swekla Peter Pivonka David ML Cooper 《Journal of bone and mineral research》2020,35(11):2211-2228
Cortical bone porosity is intimately linked with remodeling, is of growing clinical interest, and is increasingly accessible by imaging. Thus, the potential of animal models of osteoporosis (OP) to provide a platform for studying how porosity develops and responds to interventions is tremendous. To date, rabbit models of OP have largely focused on trabecular microarchitecture or bone density; some such as ovariectomy (OVX) have uncertain efficacy and cortical porosity has not been extensively reported. Our primary objective was to characterize tibial cortical porosity in rabbit-based models of OP, including OVX, glucocorticoids (GC), and OVX + GC relative to controls (SHAM). We sought to: (i) test the hypothesis that intracortical remodeling is elevated in these models; (ii) contrast cortical remodeling and porosity in these models with that induced by parathyroid hormone (1–34; PTH); and (iii) contrast trabecular morphology in the proximal tibia across all groups. Evidence that an increase in cortical porosity occurred in all groups was observed, although this was the least robust for GC. Histomorphometric measures supported the hypothesis that remodeling rate was elevated in all groups and also revealed evidence of uncoupling of bone resorption and formation in the GC and OVX + GC groups. For trabecular bone, a pattern of loss was observed for OVX, GC, and OVX + GC groups, whereas the opposite was observed for PTH. Change in trabecular number best explained these patterns. Taken together, the findings indicated rabbit models provide a viable and varied platform for the study of OP and associated changes in cortical remodeling and porosity. Intriguingly, the evidence revealed differing effects on the cortical and trabecular envelopes for the PTH model. © 2020 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).. 相似文献
53.
Auber ML; Horwitz LJ; Blaauw A; Khorana S; Tucker S; Woods T; Warmuth M; Dicke KA; McCredie KB; Spitzer G 《Blood》1988,71(1):166-172
Relatively nonmyelotoxic drugs and drug combinations were investigated for their ability to eliminate malignant cells from human bone marrow. In vitro 90% inhibitory concentration (IC90) doses were established on granulocyte macrophage colony-forming units (GM-CFU) in culture of bone marrow by using the GM-CFU assay for the following drugs: 4- hydroperoxycyclophosphamide (4-HC), Adriamycin, L-asparaginase, bleomycin, hydrocortisone, VP-16, spirogermanium, Taxol, and vincristine. The leukemic cell kill efficiency of these drugs at IC90 doses was compared with that of 4-HC on acute lymphoid leukemia (ALL) cell lines by using the limiting-dilution assay. Under these conditions, no single drug was superior to 4-HC. To increase the in vitro effect in leukemic cell kill, combinations of vincristine with hydrocortisone, Adriamycin, VP-16, and 4-HC were investigated. Vincristine at 1 to 5 micrograms/mL increased the marrow cytotoxicity of hydrocortisone, Adriamycin, and VP-16, but it was protective (subadditive) with 4-HC. Vincristine and 4-HC in combination was additive to supraadditive on ALL cell lines, increased the leukemic cell kill by one to two logs above 4-HC alone at IC90 doses (P less than .05), and was not affected by the addition of excess marrow cells. The recommended doses for chemopurging in clinical studies are vincristine, 1 to 5 micrograms/mL, plus 4-HC, 5 micrograms/mL. 相似文献
54.
55.
保证输血时血清学方面的安全,首要的是对受血者与献血者ABO血型定型,血清学检查通常分两个步骤.正定型通常使用鼠源单克隆抗体检测红细胞表面是否存在A或B抗原.互补的实验即反定型,利用当红细胞上缺乏A或B抗原时,人群可天然产生相对应的抗体的原理,检测血清中是否存在抗-A或者抗-B抗体.确定了受血者红细胞表面的ABO抗原以及血浆中的抗体,便能确定血型,为其提供相合的血液. 相似文献
56.
Abstract: The study of plasma integrates physics, chemistry, biology, and engineering, and has recently engaged medicine and dental hygiene in research efforts. The study of plasma holds promise for a myriad of applications ranging from lasers and electronics, hazardous waste management, decontamination, sterilization and disinfection of foods, soil, water, instruments, to medical uses in wound healing and treating certain types of tumours and cancers. Plasma represents a new state-of-the-art sterilization and disinfection treatment for certain oral and enviornmental pathogens, heat-sensitive materials, contaminated medical waste, hard and soft surfaces, and ventilation systems may assist health care facilities in the management of various health concerns. The role that Low Temperature Atmospheric Pressure Plasma (LTAPP) could play in the inactivation of pathogenic microorganisms might prove to be a new, faster, noncorrosive, more economical alternative, as well as support green healthcare. 相似文献
57.
保证输血时血清学方面的安全,首要的是对受血者与献血者ABO血型定型,血清学检查通常分两个步骤.正定型通常使用鼠源单克隆抗体检测红细胞表面是否存在A或B抗原.互补的实验即反定型,利用当红细胞上缺乏A或B抗原时,人群可天然产生相对应的抗体的原理,检测血清中是否存在抗-A或者抗-B抗体.确定了受血者红细胞表面的ABO抗原以及血浆中的抗体,便能确定血型,为其提供相合的血液. 相似文献
58.
59.
Jason M Redman Yo-Ting Tsai Benjamin A Weinberg Renee N Donahue Shruti Gandhy Margaret E Gatti-Mays Houssein Abdul Sater Marijo Bilusic Lisa
M Cordes Seth M Steinberg Jennifer L Marte Caroline Jochems Sunnie S Kim John L Marshall Sheri McMahon Erica Redmond Jeffrey Schlom James L Gulley Julius Strauss 《The oncologist》2022,27(3):198
BackgroundFOLFOX plus bevacizumab is a standard of care (SOC) for first-line treatment of microsatellite-stable metastatic colorectal cancer (MSS mCRC). This study randomized patients to SOC or SOC plus avelumab (anti-PD-L1) plus CEA-targeted vaccine.MethodsPatients with untreated MSS mCRC enrolled to a lead-in arm assessing safety of SOC + immuno-oncology agents (IO). Next, patients were randomized to SOC or SOC + IO. The primary endpoint was progression-free survival (PFS). Multiple immune parameters were analyzed.ResultsSix patients enrolled to safety lead-in, 10 randomized to SOC, and 10 to SOC + IO. There was no difference in median PFS comparing SOC versus SOC + IO (8.8 months (95% CI: 3.3-17.0 months) versus 10.1 months (95% CI: 3.6-16.1 months), respectively; hazard ratio 1.061 [P = .91; 95% CI: 0.380-2.966]). The objective response rate was 50% in both arms. Of patients analyzed, most (8/11) who received SOC + IO developed multifunctional CD4+/CD8+ T-cell responses to cascade antigens MUC1 and/or brachyury, compared to 1/8 who received SOC alone (P = .020). We detected post-treatment changes in immune parameters that were distinct to the SOC and SOC + IO treatment arms. Accrual closed after an unplanned analysis predicted a low likelihood of meeting the primary endpoint.ConclusionsSOC + IO generated multifunctional MUC1- and brachyury-specific CD4+/CD8+ T cells despite concurrent chemotherapy. Although a tumor-directed immune response is necessary for T-cell–mediated antitumor activity, it was not sufficient to improve PFS. Adding agents that increase the number and function of effector cells may be required for clinical benefit. 相似文献
60.